The US Centers and Disease Control and Prevention is considering recommending annual Covid-19 shots to those who are older or ...

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...

Novavax, the little-known Maryland company that received a $1.6 billion deal from the federal government for its experimental coronavirus vaccine, announced encouraging results in two preliminary ...

The Trump administration has reportedly disrupted over 100 clinical trials. Science News spoke to researchers about the impacts on four of them.

Less than a quarter of adults and around 13% of children have gotten a COVID-19 vaccination this past season, CDC data shows, ...

GeoVax was using its HHS contract to develop its next-generation multi-antigen COVID-19 vaccine, which is in Phase IIb ...

GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE) have agreed to dismiss a U.S. patent lawsuit over Pfizers RSV vaccine, ...

The CDC's vaccine committee will convene for a two-day meeting this week to consider recommendations on vaccines, including the COVID-19 vaccine for 2025-2026.

A three-year study has found robust evidence that one particular vaccine for respiratory syncytial virus (RSV) offers older ...

For meningococcal vaccines, ACIP recommended that GSK's pentavalent vaccine (Penmenvy), designed to protect against A, B, C, ...

At its first meeting under the new administration, the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted on recommendations for several ...